HLA-KMR™ HLA Loss Detection Assay’s

GenDx now supports 10 HLA-KMR markers to detect HLA loss relapse

The 10 genomic markers are all located within HLA genes and integrated in the KMRtype/KMRtrack and KMRengine workflow.

Using these 10 markers targeting some of the most frequent alleles of HLA-A, -C, and -DPB1, the loci that are most often mismatched in haploidentical and unrelated HSCT, an informative marker for HLA loss (i.e. specifically targeting an HLA allele present in the recipient but not in the donor) can be found for 70.3% of haploidentical and 66.4% matched unrelated recipient-donor pairs (these percentages are from European studies and thereby mainly represent the Caucasian population).

HLA-KMR in Chimerism Monitoring

Leukemia relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is in most cases of recipient origin and leads to a status of mixed chimerism. High sensitivity chimerism monitoring can therefore predict this frequent HSCT complication and enable timely clinical intervention. When an imminent relapse is identified by the HLA laboratory or physician, additional information on whether or not the relapse is characterized by “HLA loss” can provide valuable information for the course of treatment.

HLA Loss

In a partially HLA-mismatched allogeneic hematopoietic stem cell transplantation (HSCT), leukemia control is partly mediated by alloreactive donor T cells recognizing mismatched patient-specific HLA molecules on residual tumor cells. Relapse however remains a frequent and severe complication, and in a considerable number of cases is due to specific immune escape by leukemia via genomic loss of the mismatched HLA haplotype. These HLA loss relapses become invisible to control by alloreactive donor T cells.

Fully Integrated Workflow